Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

Hepatology

Volumn 61, Issue 3, 2015, Pages 769-775

  Lawitz, Eric ^a,b   Poordad, Fred ^a,b   Brainard, Diana M ^c   Hyland, Robert H ^c   An, Di ^c   Dvory Sobol, Hadas ^c   Symonds, William T ^c   Mchutchison, John G ^c   Membreno, Fernando E ^d  

^a Texas Liver Institute   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c GILEAD SCIENCES   (United States)

^d TEXAS TRANSPLANT INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; HEMOGLOBIN; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; RIBAVIRIN; SOFOSBUVIR; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN; URIDINE PHOSPHATE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLELE; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CHOLECYSTITIS; CLINICAL ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS VARICES BLEEDING; EVENING DOSAGE; FATIGUE; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; HYPERTENSION; INSOMNIA; LEUKOCYTE COUNT; LIMIT OF QUANTITATION; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MORNING DOSAGE; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; OPEN STUDY; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PULSE RATE; RELAPSE; SEPSIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; VIRUS RESISTANCE; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; CLASSIFICATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; SOFOSBUVIR; URIDINE MONOPHOSPHATE;

EID: 84923302656     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27567     Document Type: Article

References (20)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374.
2. Naggie S, Patel K, McHutchison J. Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. J Antimicrob Chemother 2010;65:2063-2069.
3. Tapper EB, Afdhal NH. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat 2013;20:669-677.
4. Gower E, Estes CC, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus. J Hepatol 2014 [Epub ahead of print].
5. Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology 2014;60:98-105.
6. Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology 2014;59:2403-2412.
7. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013a;368:1878-1887.
8. Assis DN, Lim JK. New pharmacotherapy for hepatitis C. Clin Pharmacol Ther 2012;92:294-305.
9. Wyles DL. Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection. Top Antivir Med 2012;20:139-145.
10. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-1877.
11. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993-2001.
12. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34-44.
13. Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013b;13:401-408.
14. Papastergiou V, Stampori M, Lisgos P, Pselas C, Prodromidou K, Karatapanis S. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study. Eur J Gastroenterol Hepatol 2013;25:798-805.
15. Svarovskaia ES, Dvory-Sobol H, Parkin N, Hebner C, Gontcharova V, et al. Infrequent development of resistance in genotype 1 through 6 HCV-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis 2014 [Epub ahead of print].
16. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-134.
17. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
18. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009;136:1618-1628.
19. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org/.
20. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392-420.